We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
(-4.8%)
Cap. Flow
+$505M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$83.5M |
| 2 |
S&P Global
SPGI
|
+$73.5M |
| 3 |
Tesla
TSLA
|
+$55.8M |
| 4 |
Microsoft
MSFT
|
+$45.9M |
| 5 |
Amazon
AMZN
|
+$27.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$88.8M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$74.7M |
| 3 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$31.7M |
| 4 |
Abbott
ABT
|
+$25.5M |
| 5 |
Exelon
EXC
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 13.53% |
| 3 | Healthcare | 13.01% |
| 4 | Consumer Discretionary | 11.66% |
| 5 | Industrials | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
2701
DELISTED
IGM Biosciences
IGMS
| $247K | ﹤0.01% |
9,222
+1,308
| +17% | +$24.4K |
|
2702
Xponential Fitness
XPOF
$211M
| $247K | ﹤0.01% |
+10,540
| New | +$206K |
|
2703
Vera Therapeutics
VERA
$2.36B
| $244K | ﹤0.01% |
+10,385
| New | +$223K |
|
2704
Invivyd
IVVD
$218M
| $243K | ﹤0.01% |
53,319
+30,463
| +133% | +$186K |
|
|
TEAD
2705
Teads Holding Co
TEAD
$67.7M
| $243K | ﹤0.01% |
+22,691
| New | +$285K |
|
2706
Rimini Street
RMNI
$471M
| $242K | ﹤0.01% |
41,664
+12,334
| +42% | +$64.8K |
|
2707
Teekay
TK
$985M
| $242K | ﹤0.01% |
76,477
+4,795
| +7% | +$15.5K |
|
2708
Nature's Sunshine
NATR
$288M
| $241K | ﹤0.01% |
14,302
-948
| -6% | -$16.8K |
|
|
AGS
2709
DELISTED
PlayAGS
AGS
| $240K | ﹤0.01% |
36,004
-904
| -2% | -$6.79K |
|
2710
Red River Bancshares
RRBI
$659M
| $240K | ﹤0.01% |
4,535
-607
| -12% | -$31.5K |
|
2711
Noodles & Co
NDLS
$107M
| $239K | ﹤0.01% |
5,003
+839
| +20% | +$51.5K |
|
2712
VistaGen Therapeutics
VTGN
$12.8M
| $239K | ﹤0.01% |
6,429
+1,195
| +23% | +$52.1K |
|
2713
Verastem
VSTM
$610M
| $236K | ﹤0.01% |
13,953
+39
| +0.3% | +$672 |
|
|
GAN
2714
DELISTED
GAN Ltd
GAN
| $235K | ﹤0.01% |
48,704
+1,867
| +4% | +$12K |
|
2715
iShares S&P Small-Cap 600 Value ETF
IJS
$8.37B
| $235K | ﹤0.01% |
+2,300
| New | +$234K |
|
2716
Superior Group of Companies
SGC
$225M
| $235K | ﹤0.01% |
13,150
-1,361
| -9% | -$27K |
|
2717
Credicorp
BAP
$30.7B
| $234K | ﹤0.01% |
+1,362
| New | +$206K |
|
|
GRTS
2718
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $234K | ﹤0.01% |
56,865
+1,170
| +2% | +$6.2K |
|
2719
Janux Therapeutics
JANX
$967M
| $233K | ﹤0.01% |
16,216
+5,179
| +47% | +$84.7K |
|
2720
Vitamin Cottage Natural Grocers
NGVC
$654M
| $233K | ﹤0.01% |
11,908
-747
| -6% | -$12.4K |
|
2721
Comscore
SCOR
$109M
| $233K | ﹤0.01% |
3,998
+53
| +1% | +$3.04K |
|
2722
Traeger
COOK
$172M
| $232K | ﹤0.01% |
625
+176
| +39% | +$83.9K |
|
2723
CorMedix
CRMD
$584M
| $232K | ﹤0.01% |
42,331
-1,018
| -2% | -$4.66K |
|
2724
INNOVATE Corp
VATE
$165M
| $232K | ﹤0.01% |
6,284
+236
| +4% | +$8.76K |
|
|
CLVS
2725
DELISTED
Clovis Oncology, Inc.
CLVS
| $231K | ﹤0.01% |
114,265
+1,388
| +1% | +$2.73K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
- RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
- RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
- RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
- RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
- RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.